高级检索
当前位置: 首页 > 详情页

Overexpression of miR-96 promotes cell proliferation by targeting FOXF2 in prostate cancer

| 认领 | 导出 |

文献详情

资源类型:
机构: [1]Sichuan Univ, West China Hosp, Dept Urol, Inst Urol, Chengdu, Sichuan, Peoples R China [2]Sichuan Univ, West China Hosp, Dept Vasc Surg, Chengdu, Sichuan, Peoples R China [3]Sichuan Univ, West China Hosp, Dept Liver Surg, Chengdu, Sichuan, Peoples R China [4]Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Sichuan, Peoples R China [5]Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Sichuan, Peoples R China [6]Sichuan Univ, West China Univ Hosp 2, Dept Pediat, 20,Sect 3,Renmin South Rd, Chengdu, Sichuan, Peoples R China [7]Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, 20,Sect 3,Renmin South Rd, Chengdu, Sichuan, Peoples R China
出处:
ISSN:

关键词: Prostate cancer miR-96 FOXF2 cell proliferation

摘要:
Prostate cancer (PC) is one of the most common cancers in males. MicroRNAs (miRNAs) are demonstrated to be involved in prostate cancer development and progression. Recently, miR-96 was identified to play a tumor promoting role in several tumors including PC, however, the underlying function of miR-96 in PC still need to be known. In the study, our results demonstrated that miR-96 was higher in prostate cancer tissues compared with adjacent normal tissues. Higher miR-96 was association with higher PSA level, lymph node metastasis, pathologic stage and distant metastasis in prostate cancer patients. Lose-of-function studies showed that down-regulated expression of miR-96 inhibited cell proliferation and cell cycle by regulating down-regulating CyclinA1, CDK2 and CDK4 expression in PC cells. Furthermore, we found that FOXF2 was a target of miR-96 in PC cells and miR-96 promoted cell proliferation by suppressing FOXF2 expression. Thus, these results showed that inhibition of miR-96 may be a target for prostate cancer treatment.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
最新[2023]版:
第一作者:
第一作者机构: [1]Sichuan Univ, West China Hosp, Dept Urol, Inst Urol, Chengdu, Sichuan, Peoples R China
通讯作者:
通讯机构: [5]Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Sichuan, Peoples R China [6]Sichuan Univ, West China Univ Hosp 2, Dept Pediat, 20,Sect 3,Renmin South Rd, Chengdu, Sichuan, Peoples R China [7]Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, 20,Sect 3,Renmin South Rd, Chengdu, Sichuan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号